Cargando…

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and minimize growth of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebos, John ML, Mastri, Michalis, Lee, Christina R, Tracz, Amanda, Hudson, John M, Attwood, Kristopher, Cruz-Munoz, William R, Jedeszko, Christopher, Burns, Peter, Kerbel, Robert S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287975/ https://www.ncbi.nlm.nih.gov/pubmed/25361689 http://dx.doi.org/10.15252/emmm.201403989

Ejemplares similares

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Tumor growth fueled by spurious senescence phenotypes
por: Mastri, Michalis, et al.
Publicado: (2019)

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
por: Vaghi, Cristina, et al.
Publicado: (2020)

Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth
por: Benzekry, Sébastien, et al.
Publicado: (2014)

A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
por: Di Matteo, P, et al.
Publicado: (2013)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer
por: Moisuc, Diana Cornelia, et al.
Publicado: (2022)

Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009)

Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope
por: Medina, Miguel Ángel, et al.
Publicado: (2007)

The Differential Paracrine Role of the Endothelium in Prostate Cancer Cells
por: Torres-Estay, Verónica, et al.
Publicado: (2022)

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography
por: Zhu, Xiao-Dong, et al.
Publicado: (2011)

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
por: Larrayoz, Marta, et al.
Publicado: (2014)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin
por: del Amo, Eva M., et al.
Publicado: (2020)

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
por: Hofheinz, R.-D., et al.
Publicado: (2016)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

Antiangiogenic platinum through glycan targeting
por: Peterson, Erica J., et al.
Publicado: (2017)

Antiangiogenic therapy for breast cancer
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2010)

Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Antiangiogenic Therapy for Diabetic Nephropathy
por: Tanabe, Katsuyuki, et al.
Publicado: (2017)

Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers
por: Ellegate, James, et al.
Publicado: (2022)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Antiangiogenic Activity of 2-Deoxy-D-Glucose
por: Merchan, Jaime R., et al.
Publicado: (2010)

Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib
por: Zhang, Cathy C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c5eo5k0r7k0bl42g9bfrp3oaa8